Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
3
4
2020
medline:
25
6
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
Identifiants
pubmed: 32240071
doi: 10.1200/JOP.19.00517
pmc: PMC7427420
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e751-e757Subventions
Organisme : NCI NIH HHS
ID : R01 CA197792
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA234701
Pays : United States
Références
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
J Clin Oncol. 2019 May 10;37(14):1228-1263
pubmed: 30932732
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Clin Chem. 2015 Feb;61(2):360-7
pubmed: 25451866
Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7
pubmed: 23956208
Ann Clin Lab Sci. 2009 Spring;39(2):144-9
pubmed: 19429800
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
JAMA Oncol. 2018 Sep 1;4(9):1221-1227
pubmed: 29800065
Br J Cancer. 2000 Nov;83(10):1261-7
pubmed: 11044347
Am J Hematol. 2016 Jul;91(7):719-34
pubmed: 27291302